NCT02325219 - An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis | Biotech Hunter

Enrollment

192

Participants

Timeline

Start Date

December 19, 2014

Primary Completion Date

March 2, 2016

Study Completion Date

February 8, 2019

Conditions

Psoriasis

Interventions

DRUG

CNTO 1959 50 mg

Participants will receive subcutaneous injection of CNTO 1959 50 mg.

DRUG

CTNO 1959 100 mg

Participants will receive subcutaneous injection of CNTO 1959 100 mg.

DRUG

Placebo 50 mg

Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.

DRUG

Placebo 100 mg

Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.

Trial Locations (27)

Unknown

Asahikawa

Chūō

Gifu

Isehara

Izumo

Kanazawa

Kawasaki

Kita-Gun

Kochi

Kurume

Kyoto

Matsumoto

Miyagi

Morioka

Nagoya

Osaka

Ōsaka-sayama

Sapporo

Shimotsuke

Shinjuku-ku

Tokushima

Tokyo

Tōon

Tsu

Tsukuba

Ube

Yokosuka